Karyopharm Therapeutics (NASDAQ:KPTI) Posts Earnings Results

Karyopharm Therapeutics (NASDAQ:KPTI) released its earnings results on Thursday. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95), FiscalAI reports. The firm had revenue of $33.43 million during the quarter, compared to the consensus estimate of $32.19 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Myelofibrosis sNDA remains on track for August 2026 under the FDA’s Accelerated Approval pathway, supported by rapid, deep, and sustained spleen-volume responses in the SENTRY trial and constructive FDA discussions.
• If approved, selinexor plus ruxolitinib could become the first approved combination therapy for myelofibrosis, with a potential launch as early as the first quarter of 2027 and estimated U.S. peak annual revenue of approximately $1 billion.
• Liquidity remains a significant risk: Karyopharm had $65.4 million in cash and investments at quarter-end, expects funding only into September 2026, and faces a $16.8 million term-loan payment on September 10 that could trigger a covenant breach without new financing, a waiver, or a strategic transaction.
• The company is reducing investment in endometrial cancer after the XPORT-EC-042 Phase III trial failed to reach statistical significance, while focusing resources on myelofibrosis and multiple myeloma; XPOVIO U.S. revenue nevertheless rose to $30.8 million from $29.7 million year over year.

Karyopharm Therapeutics Stock Down 1.7%

NASDAQ KPTI traded down $0.04 during trading hours on Thursday, reaching $2.00. The company’s stock had a trading volume of 1,221,486 shares, compared to its average volume of 974,383. The company has a market capitalization of $45.21 million, a price-to-earnings ratio of -0.13 and a beta of 0.89. Karyopharm Therapeutics has a 1 year low of $1.80 and a 1 year high of $10.99. The firm’s 50-day moving average price is $7.75 and its 200-day moving average price is $7.93.

Analyst Ratings Changes

KPTI has been the topic of a number of analyst reports. HC Wainwright cut Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research report on Friday, July 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Karyopharm Therapeutics in a report on Tuesday, June 9th. Royal Bank Of Canada reissued an “outperform” rating and issued a $16.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, July 21st. Robert W. Baird downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research report on Friday, July 31st. Finally, Piper Sandler reduced their price objective on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.50.

Institutional Trading of Karyopharm Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. boosted its stake in shares of Karyopharm Therapeutics by 112.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock valued at $10,977,000 after purchasing an additional 790,417 shares in the last quarter. Ikarian Capital LLC grew its holdings in Karyopharm Therapeutics by 1,897.9% in the fourth quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock valued at $4,008,000 after purchasing an additional 517,297 shares during the period. Geode Capital Management LLC raised its position in Karyopharm Therapeutics by 101.2% during the fourth quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock worth $1,382,000 after acquiring an additional 94,445 shares during the period. Bank of America Corp DE lifted its stake in Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after buying an additional 35,626 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at approximately $1,064,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.